All In Biotech

Drug Trial Radar · NCT06680830

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 17, 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Neuron23 Inc.Industry
Sponsor type
Industry
Collaborators
Qiagen Manchester Limited; Roche Diagnostic Ltd.
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

Conditions

  • Parkinson Disease
  • Parkinson
  • Idiopathic Parkinson Disease
  • Early Parkinson Disease (Early PD)
  • Parkinson Disease, Idiopathic

Interventions

  • NEU-411Drug

    NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity

  • PlaceboOther

    Orally-administered matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Roche digital biomarker score using the Roche Parkinson's Disease application (v3.0) compared to placeboTime frame: From enrollment to the end of treatment at 52 weeks
  2. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placeboTime frame: From enrollment to the end of study at 54 weeks

Locations

72 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner Sun Health Research Institute

    Sun City, Arizona · Recruiting

  • University of Arkansas

    Little Rock, Arkansas · Recruiting

  • Neuro-Pain Medical Center

    Fresno, California · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Esperanza Clinical

    Murrieta, California · Completed

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California · Recruiting

  • Sutter Neuroscience Institute

    Sacramento, California · Recruiting

  • University of Colorado - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Neurology One

    Orlando, Florida · Recruiting

  • USF Parkinson's & Movement Disorders Clinic

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Augusta University

    Augusta, Georgia · Recruiting

  • Northwestern Medical Group, Department of Neurology

    Chicago, Illinois · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Quest Research Institute

    Farmington Hills, Michigan · Recruiting

  • Struthers Parkinson Center

    Golden Valley, Minnesota · Recruiting

  • Cleveland Clinic

    Las Vegas, Nevada · Recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • Northwell Health

    Manhasset, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai/Mount Sinai West

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma · Recruiting

  • Oregon Health & Science University (OHSU)

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Vanderbilt University

    Nashville, Tennessee · Recruiting

  • Neurology Consultants of Dallas PA

    Dallas, Texas · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

  • Central Texas Neurology Consultants

    Round Rock, Texas · Recruiting

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.